# Description of the cutaneous manifestations of Covid-19 (COVID-PIEL)

**First published:** 02/04/2020

**Last updated:** 11/09/2024

Study Planned

## Administrative details

**EU PAS number**

EUPAS34469

**Study ID**

34470

**DARWIN EU® study**

No

**Study countries**

☐ Spain

**Study description**

Observational transversal descriptive study with the main objective to describe the clinical characteristics and symptoms of the cutaneous manifestations associated with COVID-19.The secondary objectives are:o Identify the

chronology of the cutaneous manifestations associated with COVID-19.o Evaluate the eventual relationship of skin manifestations with current COVID-19 treatments.o Evaluate the relationship of cutaneous manifestations associated with analytical parameters.

**Study status**

Planned

# Research institutions and networks

## Institutions

### Hospital Universitario de Móstoles

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

### Hospital Plato Barcelona, Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria

# Contact details

**Study institution contact**

Cristina Galvan Casas covidpiel@gmail.com

**Study contact**

covidpiel@gmail.com

**Primary lead investigator**

Cristina Galvan Casas

**Primary lead investigator**

## Study timelines

**Date when funding contract was signed**
Planned: 31/03/2020

**Study start date**
Planned: 06/04/2020

**Data analysis start date**
Planned: 21/04/2020

**Date of interim report, if expected**
Planned: 21/04/2020

**Date of final study report**
Planned: 30/04/2020

## Sources of funding

- Other

## More details on funding

Principal Investigators

## Regulatory

**Was the study required by a regulatory body?**

No

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Other study registration identification numbers and links

ACG-CLO2020-01Agencia Española del Medicamento

# Methodological aspects

## Study type

## Study type list

**Study type:**

Non-interventional study

**Scope of the study:**

Disease epidemiology

**Main study objective:**

To describe the clinical characteristics and symptoms of the cutaneous manifestations associated with COVID-19.

## Study Design

**Non-interventional study design**

Cross-sectional

## Study drug and medical condition

**Medical condition to be studied**

Rash erythematous

## Population studied

**Age groups**

Preterm newborn infants (0 – 27 days)

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

**Special population of interest**

Hepatic impaired

Immunocompromised

Pregnant women

Renal impaired

---

**Estimated number of subjects**

60

## Study design details

**Outcomes**

o Identify the chronology of the cutaneous manifestations associated with COVID-19.o Evaluate the eventual relationship of skin manifestations with current COVID-19 treatments.o Evaluate the relationship of cutaneous manifestations associated with analytical parameters

---

**Data analysis plan**

The statistical analysis includes descriptive statistics using absolute frequencies and percentages. The chi-square test and odds ratio calculation will be used to test the association between skin manifestations, COVID-19 treatments and analytical parameters indicating severity.

# Data management

## Data sources

**Data sources (types)**

Spontaneous reports of suspected adverse drug reactions

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

**Check completeness**

Unknown

**Check stability**

Unknown

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No